Sentences with phrase «in pediatric brain tumors»

The St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high - grade gliomas (HGGs), which most often occur in the youngest patients.

Research from the Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high - grade gliomas, including tumors like diffuse intrinsic pontine glioma pictured in this MRI.

As these compounds are already approved for clinical trails in pediatric brain tumors, these findings suggest that drugs inhibiting MEK activity could offer a new therapy option for children with these devastating tumors.

Two Emory researchers are being recognized by the Southeastern Brain Tumor Foundation (SBTF) for their work in pediatric brain tumor research.

Not exact matches

Frustrated with the lack of investment in research and drug development devoted to pediatric brain tumor gliomas, the Kamens decided to take action and launch their foundation.

The Kamens claim the main thing that distinguishes their foundation from other brain tumor foundations is their focus on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.

He has also authored several chapters in scholarly texts on subjects ranging from pediatric concussion to brain tumors in children.

He remains a leader in supportive care and research in pediatric oncology, with a special focus on neuroblastoma, non-Hodgkin lymphoma, Ewing Sarcoma, acute lymphoblastic leukemia and brain tumors.

In particular, our pediatric radiation oncologists at Floating Hospital for Children offer special expertise in the management of brain tumors, including medulloblastoma, with a combination of post-operative radiotherapy and multi-agent chemotherapIn particular, our pediatric radiation oncologists at Floating Hospital for Children offer special expertise in the management of brain tumors, including medulloblastoma, with a combination of post-operative radiotherapy and multi-agent chemotherapin the management of brain tumors, including medulloblastoma, with a combination of post-operative radiotherapy and multi-agent chemotherapy.

Engineered human immune cells can vanquish a deadly pediatric brain tumor in a mouse model, a study from the Stanford University School of Medicine has demonstrated.

It also features prominently in pediatric cancers such as medulloblastoma, a rare brain tumor.

Pilocytic astrocytoma (PA) is a primarily pediatric brain tumor caused mainly by mutations in the BRAF gene.

«Carefully defining the molecular landscape of these tumor subtypes may guide us in pediatric precision medicine, to better treat children with brain tumors,» said Payal Jain, PhD, a postdoctoral researcher at Children's Hospital of Philadelphia (CHOP).

«Biology of childhood brain tumor subtypes offers clues to precision treatments: Researchers reveal differences among gene fusions in low - grade pediatric brain tumors.»

Sanford Research scientists are published in Nature Cell Biology for their work developing a model to explore therapies for a pediatric brain tumor known as choroid plexus carcinoma.

Researchers investigating pediatric low - grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood cancer.

Medulloblastoma is diagnosed in about 400 children and adolescents annually in the U.S., making it the nation's most common pediatric brain tumor.

Medulloblastoma occurs in infants, children and adults, but it is the most common malignant pediatric brain tumor.

Medulloblastoma is diagnosed in about 400 children annually in the U.S., making it the most common pediatric brain tumor.

In a previous study, Sredni and colleagues were the first to describe PLK4 as a therapeutic target for brain tumors and in pediatric canceIn a previous study, Sredni and colleagues were the first to describe PLK4 as a therapeutic target for brain tumors and in pediatric cancein pediatric cancer.

Previously, the authors of the study have shown that an experimental drug that inhibits polo - like kinase 4 (PLK4) stopped pediatric brain tumor growth in vitro.

«This is exciting because it's the first animal model of pediatric high - grade gliomas, or malignant brain tumors,» says Maria Castro, Ph.D., senior author of the paper and a professor in the departments of Neurosurgery and Cell and Developmental Biology at U-M.

A new PNAS paper from geneticist Tamara Caspary's lab identifies a possible drug target in medulloblastoma, the most common pediatric brain tumor.

UT Southwestern Medical Center's pediatric brain tumor team has dedicated subspecialists, state - of - the - art radiation technology, and access to advanced pediatric treatments that other hospitals in North Texas don't offer.

UT Southwestern's pediatric neurosurgeons are some of the most gifted neurosurgeons in the country and have, along with their colleagues in neuro - oncology, radiation oncology, and neuro - radiology, dedicated their lives to the care of children with brain tumors.

We treat 80 to 100 children with brain tumors each year, and we established the first pediatric neuro - oncology program in Texas.

The University of Michigan is a national leader in basic, translational, and clinical research on pediatric brain tumors.

In this conference, members of the U-M pediatric brain tumor team and physicians from leading national brain tumor institutions incorporate molecular results from pediatric brain tumors (Mi - Oncoseq and molecular pathology) into targeted treatments for patients.

C.S. Mott Children's Hospital has expertise in treating the full range of pediatric brain tumor types, including:

U-M is emerging as a leader in the care for and research into better treatments for pediatric brain tumors.

He continues to study cancer gene function in his Georgetown lab, and has recently identified a new cancer gene called STAG2 that is among the most commonly mutated genes in cancer, involved in causing bladder cancer, pediatric bone tumors, leukemias, brain tumors, and other tumor types.

Our groundbreaking Pediatric Mi - Oncoseq Program is an internationally known precision oncology program focusing on the genetic analysis of pediatric cancer patients including in children with malignant brain tumors, and determines whether targeted treatments may be available based upon their personalized tumor genomic sequencing profiles.